Novel Urokinase-Type Plasminogen Activator Receptor-Targeting Optical Imaging Agent ICG-Glu-Glu-AE105 for Visualization of Malignant Glioma During Surgery: First-in-Human Study in 35 Patients with Brain Cancer
FG001 was found to be safe and well tolerated in the patients included in the study. The optimal dose of FG001 was selected on the basis of videos taken during the surgery and the measured TBR values. A dose of 36 mg administered 16 hours (mean) before the surgery showed the best contrast (TBR values) and optimal visualization of the tumor delineation. Histology demonstrated good sensitivity of FG001.
Authors
- Jane Skjøth‐Rasmussen (ORCID: https://orcid.org/0000-0001-8689-9704)
- Sara Ginsborg
- Bjarne Winther Kristensen (ORCID: https://orcid.org/0000-0002-6352-0826)
- Christine Sølling (ORCID: https://orcid.org/0000-0002-0724-4695)
- Martin Kryspin Sørensen (ORCID: https://orcid.org/0000-0002-6875-5341)
- ANM Nure Azam (ORCID: https://orcid.org/0000-0001-8744-0401)
- Karina Juhl (ORCID: https://orcid.org/0000-0002-8266-8260)
- David Scheie (ORCID: https://orcid.org/0000-0002-9772-8828)
- Carl Christian Larsen (ORCID: https://orcid.org/0009-0000-9554-0031)
- Andreas Kjær (ORCID: https://orcid.org/0000-0002-0096-5764)
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Neurosurgery
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1227/neu.0000000000003542
- Citations
- 4
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.50
Funders
- Innovationsfonden
- European Commission
- National Research Foundation
- Danmarks Grundforskningsfond
- Lundbeckfonden
- Novo Nordisk
- H. Lundbeck A/S